Related Experiment Video

Updated: Jul 27, 2026

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

Novel approaches to treating cardiovascular disease: lessons from Tangier disease

J F Oram1

  • 1University of Washington, Department of Medicine, Seattle, Washington, WA 98195-6426, USA. joram@u.washington.edu

Expert Opinion on Investigational Drugs
|February 28, 2001
PubMed

Insights

Novel therapies targeting ATP binding cassette transporter ABCA1 show promise for treating atherosclerotic cardiovascular disease (CVD). Stimulating ABCA1 can reduce cholesterol, potentially treating CVD by clearing plaques.

Area of Science:

  • Biochemistry
  • Cardiovascular Medicine
  • Genetics

Background:

  • Atherosclerotic cardiovascular disease (CVD) is a leading cause of death, with cholesterol management having limited success.
  • The ATP binding cassette transporter ABCA1 plays a crucial role in cholesterol efflux from macrophages into high-density lipoprotein (HDL) metabolism.
  • Defects in ABCA1 cause Tangier disease, characterized by HDL deficiency, cholesterol accumulation, and atherosclerosis.

Purpose of the Study:

  • To explore ABCA1 as a therapeutic target for cardiovascular disease.
  • To investigate the potential of drugs that stimulate ABCA1 activity for CVD treatment.

Main Methods:

  • Studied the role of ABCA1 in cholesterol metabolism and HDL pathways.
  • Examined the effects of ABCA1 induction in mouse models.
  • Investigated the impact of ABCA1 on cholesterol clearance and absorption.

Main Results:

  • ABCA1 activity correlates with plasma HDL levels and CVD susceptibility.
  • Drugs inducing ABCA1 in mice enhanced cholesterol clearance from tissues.
  • ABCA1-stimulating drugs inhibited dietary cholesterol absorption.

Conclusions:

  • ABCA1-stimulating drugs offer a novel therapeutic strategy for CVD.
  • These drugs can mobilize cholesterol from atherosclerotic lesions and reduce body cholesterol.
  • Targeting ABCA1 may reduce plaque formation and rupture, independent of traditional atherogenic factors.

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...